Across TCGA pan-cancer cohorts, PLA2G1B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PLA2G1B data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher PLA2G1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2G1B expression acts as an unfavorable survival marker.
COAD and SKCM are the cancer types where PLA2G1B Mutation most reproducibly stratifies survival.